InfraScan Launches International Sales of its Ruggedized Handheld Brain Hematoma Detector
November 08, 2012 --
Philadelphia, PA (PRWEB) November 08, 2012
InfraScan, a medical device company specializing in brain injury diagnostic products, announced today that it has obtained the Health Canada clearance and the CE Mark, the European marketing clearance, for the Infrascanner Model 2000, a ruggedized handheld brain hematoma detector. InfraScan will launch international sales of the Infrascanner Model 2000 at the worlds largest medical trade show, MEDICA in Dusseldorf, held on November 1417, 2012, where InfraScan will exhibit at the PA Booth in Hall 16 G05.
The Infrascanner Model 2000 is a handheld device that uses Near-Infrared (NIR) technology to detect intracranial bleeding, identifying those patients who would most benefit from immediate referral to a CT scan and neurosurgical intervention. In the triage of head trauma patients, the Infrascanner can identify patients most likely to have intracranial bleeding.
The Infrascanner Model 2000 is based on the Infrascanner Model 1000, following the specifications of the US Marine Corps. The US Navy and Marines supported the development of the technology. The improvements in the Infrascanner Model 2000 include:
- Integration of the processing, display and control functions of the separate PDA into the sensor.
- Ruggedization of the system for improved reliability.
- Ability to use disposable AA batteries in addition to a rechargeable battery pack.
The Infrascanner is designed to assist first responders and emergency room personnel in identifying life threatening brain hematomas, allowing expedient assessment of patients and potentially facilitating life-saving treatment. An estimated 1.5 million individuals seek medical treatment for head trauma in the U.S. each year, and a total of 10 million individuals seek head trauma treatment annually worldwide. Intracranial hematomas resulting from a traumatic brain injury are life-threatening and have been reported to occur as the primary injury in 40% of patients with severe head injury. Successful treatment often relies upon timely diagnosis and intervention prior to neurological deterioration. The early identification of a brain hematoma can play a significant role in facilitating transportation of critically injured patients to facilities, which can both verify Infrascanners early diagnosis and offer surgical intervention. The system is currently under review by the US FDA.
To learn more about InfraScan and their products visit them at the PA Booth in Hall 16 G05!
About InfraScan InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The company has received funding from the U.S. Marine Corps, the Office of Naval Research, BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, the Ben Franklin Technology Partners of Southeastern Pennsylvania, and from the Philadelphia Industrial Development Corporation.
Read the full story at http://www.prweb.com/releases/2012/InfraScan/prweb10101252.htm.